Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Mar 21, 2022 (5 years ago)

SYMJEPI (epinephrine injection, USP)

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

SYMJEPI (epinephrine injection, USP) 0.15 mg (0.15 mg/0.3 mL), Two Pre-Filled Single-Dose Syringes per carton, Rx Only, Manufactured for Adamis Pharmaceuticals Corp.; San Diego, CA 92130; Distributed by USWM, LLC., Louisville, KY 40241, Made in Belgium, NDC 78670-131-02.

Affected NDC 78670-0131-02

Compare with the code on your package — it is the most precise check available.

Drug: Epinephrine

Recalling firm
Adamis Pharmaceuticals Corporation
NDC code
78670-131-02
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0764-2022 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Epinephrine recalls

See all
Class I · High risk

Epinephrine Injection

Presence of Particulate Matter and Lack of Assurance of Sterility. Particulate matter identified as nylon, cellulosic, acrylic, polyethylene and glass and broken and leaking vials.

Ongoing Sterility / contamination American Regent, Inc. NDC 0517-3030-01 D-0865-2026
Class II · Moderate risk

Maximum

Stability Data Does Not Support Expiry Date.

Ongoing Stability / shelf life HTO Nevada Inc. dba Kirkman D-0387-2026

Other recalls by Adamis Pharmaceuticals Corporation

All 2022 recalls
Class I · High risk

SYMJEPI (epinephrine injection, USP)

Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.

Terminated Packaging defect Adamis Pharmaceuticals Corporation NDC 78670-130-02 D-0763-2022